These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
523 related articles for article (PubMed ID: 31277699)
1. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Xing Y; Lin NU; Maurer MA; Chen H; Mahvash A; Sahin A; Akcakanat A; Li Y; Abramson V; Litton J; Chavez-MacGregor M; Valero V; Piha-Paul SA; Hong D; Do KA; Tarco E; Riall D; Eterovic AK; Wulf GM; Cantley LC; Mills GB; Doyle LA; Winer E; Hortobagyi GN; Gonzalez-Angulo AM; Meric-Bernstam F Breast Cancer Res; 2019 Jul; 21(1):78. PubMed ID: 31277699 [TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. Lee JB; Jung M; Beom SH; Kim GM; Kim HR; Choi HJ; Sohn JH; Ahn JB; Rha SY; Chung HC Invest New Drugs; 2021 Oct; 39(5):1366-1374. PubMed ID: 33723724 [TBL] [Abstract][Full Text] [Related]
3. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Stemke-Hale K; Gonzalez-Angulo AM; Lluch A; Neve RM; Kuo WL; Davies M; Carey M; Hu Z; Guan Y; Sahin A; Symmans WF; Pusztai L; Nolden LK; Horlings H; Berns K; Hung MC; van de Vijver MJ; Valero V; Gray JW; Bernards R; Mills GB; Hennessy BT Cancer Res; 2008 Aug; 68(15):6084-91. PubMed ID: 18676830 [TBL] [Abstract][Full Text] [Related]
4. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Sangai T; Akcakanat A; Chen H; Tarco E; Wu Y; Do KA; Miller TW; Arteaga CL; Mills GB; Gonzalez-Angulo AM; Meric-Bernstam F Clin Cancer Res; 2012 Oct; 18(20):5816-28. PubMed ID: 22932669 [TBL] [Abstract][Full Text] [Related]
5. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women. Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324 [TBL] [Abstract][Full Text] [Related]
6. A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III Ma CX; Suman V; Goetz MP; Northfelt D; Burkard ME; Ademuyiwa F; Naughton M; Margenthaler J; Aft R; Gray R; Tevaarwerk A; Wilke L; Haddad T; Moynihan T; Loprinzi C; Hieken T; Barnell EK; Skidmore ZL; Feng YY; Krysiak K; Hoog J; Guo Z; Nehring L; Wisinski KB; Mardis E; Hagemann IS; Vij K; Sanati S; Al-Kateb H; Griffith OL; Griffith M; Doyle L; Erlichman C; Ellis MJ Clin Cancer Res; 2017 Nov; 23(22):6823-6832. PubMed ID: 28874413 [No Abstract] [Full Text] [Related]
7. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Garrido-Castro AC; Saura C; Barroso-Sousa R; Guo H; Ciruelos E; Bermejo B; Gavilá J; Serra V; Prat A; Paré L; Céliz P; Villagrasa P; Li Y; Savoie J; Xu Z; Arteaga CL; Krop IE; Solit DB; Mills GB; Cantley LC; Winer EP; Lin NU; Rodon J Breast Cancer Res; 2020 Nov; 22(1):120. PubMed ID: 33138866 [TBL] [Abstract][Full Text] [Related]
8. Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. Herberts C; Murtha AJ; Fu S; Wang G; Schönlau E; Xue H; Lin D; Gleave A; Yip S; Angeles A; Hotte S; Tran B; North S; Taavitsainen S; Beja K; Vandekerkhove G; Ritch E; Warner E; Saad F; Iqbal N; Nykter M; Gleave ME; Wang Y; Annala M; Chi KN; Wyatt AW Eur Urol; 2020 Dec; 78(6):834-844. PubMed ID: 32451180 [TBL] [Abstract][Full Text] [Related]
9. Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients. Li G; Guo X; Chen M; Tang L; Jiang H; Day JX; Xie Y; Peng L; Xu X; Li J; Wang S; Xiao Z; Dai L; Wang J PLoS One; 2018; 13(9):e0203495. PubMed ID: 30212483 [TBL] [Abstract][Full Text] [Related]
10. Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. Myers AP; Konstantinopoulos PA; Barry WT; Luo W; Broaddus RR; Makker V; Drapkin R; Liu J; Doyle A; Horowitz NS; Meric-Bernstam F; Birrer M; Aghajanian C; Coleman RL; Mills GB; Cantley LC; Matulonis UA; Westin SN Int J Cancer; 2020 Jul; 147(2):413-422. PubMed ID: 31714586 [TBL] [Abstract][Full Text] [Related]
11. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070 [TBL] [Abstract][Full Text] [Related]
12. Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial. Kalinsky K; Sparano JA; Zhong X; Andreopoulou E; Taback B; Wiechmann L; Feldman SM; Ananthakrishnan P; Ahmad A; Cremers S; Sireci AN; Cross JR; Marks DK; Mundi P; Connolly E; Crew KD; Maurer MA; Hibshoosh H; Lee S; Hershman DL Clin Transl Oncol; 2018 Nov; 20(11):1474-1483. PubMed ID: 29736694 [TBL] [Abstract][Full Text] [Related]
13. BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Turner NC; Alarcón E; Armstrong AC; Philco M; López Chuken YA; Sablin MP; Tamura K; Gómez Villanueva A; Pérez-Fidalgo JA; Cheung SYA; Corcoran C; Cullberg M; Davies BR; de Bruin EC; Foxley A; Lindemann JPO; Maudsley R; Moschetta M; Outhwaite E; Pass M; Rugman P; Schiavon G; Oliveira M Ann Oncol; 2019 May; 30(5):774-780. PubMed ID: 30860570 [TBL] [Abstract][Full Text] [Related]
14. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Meric-Bernstam F; Akcakanat A; Chen H; Do KA; Sangai T; Adkins F; Gonzalez-Angulo AM; Rashid A; Crosby K; Dong M; Phan AT; Wolff RA; Gupta S; Mills GB; Yao J Clin Cancer Res; 2012 Mar; 18(6):1777-89. PubMed ID: 22422409 [TBL] [Abstract][Full Text] [Related]
15. Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression. Welt A; Wiesweg M; Theurer S; Abenhardt W; Groschek M; Müller L; Schröder J; Tewes M; Chiabudini M; Potthoff K; Bankfalvi A; Marschner N; Schuler M; Breitenbücher F Cancer Med; 2020 Jul; 9(13):4527-4539. PubMed ID: 32352244 [TBL] [Abstract][Full Text] [Related]
16. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. Gris-Oliver A; Palafox M; Monserrat L; Brasó-Maristany F; Òdena A; Sánchez-Guixé M; Ibrahim YH; Villacampa G; Grueso J; Parés M; Guzmán M; Rodríguez O; Bruna A; Hirst CS; Barnicle A; de Bruin EC; Reddy A; Schiavon G; Arribas J; Mills GB; Caldas C; Dienstmann R; Prat A; Nuciforo P; Razavi P; Scaltriti M; Turner NC; Saura C; Davies BR; Oliveira M; Serra V Clin Cancer Res; 2020 Jul; 26(14):3720-3731. PubMed ID: 32220884 [TBL] [Abstract][Full Text] [Related]
17. Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone. Xu B; Guan Z; Shen Z; Tong Z; Jiang Z; Yang J; DeSilvio M; Russo M; Leigh M; Ellis C Breast Cancer Res; 2014 Jul; 16(4):405. PubMed ID: 25056500 [TBL] [Abstract][Full Text] [Related]
18. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764 [TBL] [Abstract][Full Text] [Related]
19. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies. Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640 [TBL] [Abstract][Full Text] [Related]
20. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer. Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Iwase H Mol Cancer; 2018 Feb; 17(1):67. PubMed ID: 29482551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]